Moving from small-molecule analysis to tissue-based mRNA therapeutics means navigating a matrix where your target differs from the native animal background by as little as two amino acids. If you haven't verified that your surrogate peptide is genuinely unique, you risk reporting "clean" LC-MS data that is actually masked by endogenous interference.
This executive summary, featuring Shane Karnik of Aliri Bioanalysis, outlines a systematic approach to bottom-up bioanalysis. It provides the decision roadmap for screening out unstable candidates and locking in digestion parameters that remain stable in complex tissue extracts.
Download this executive summary to learn:
- How computational screening ensures your surrogate peptide does not mirror native background proteins
- Why high-resolution MS is required to identify sequences that maintain stability through the tryptic digest
- Which validation parameters confirm recovery before moving assays to routine triple quadrupole platforms
Meet the Expert:
 | Shane Karnik Senior Laboratory Director, Aliri Bioanalysis Shane Karnik is the Senior Laboratory Director at Aliri Bioanalysis. He leads a team of bioanalytical scientists supporting non-GLP and GLP preclinical and clinical studies for a variety of biopharmaceutical drugs in development. He holds a master’s degree in chemistry from the University of Colorado (USA) and has extensive R&D and pharmaceutical industry experience. |
